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Abstract
The  sperm  protein  associated  with  the
nucleus in the X chromosome (SPANX) gene
family encodes for proteins that are not only
expressed in germ cells, but also in a number
of tumors. In addition, SPANX genes map in an
interval of the X chromosome (namely, Xq27),
which has been found to be associated with
familial  prostate  cancer  by  linkage  analysis.
The aim of this study was therefore to evaluate
SPANX protein expression in normal prostate
tissues  and  in  prostate  carcinoma.  For  this
purpose,  formalin-fixed  and  paraffin-embed-
ded  sections  obtained  from  15  normal  (at
autopsy) donors and 12 men with prostate can-
cer were analyzed by immunohistochemistry.
About 40% of both normal and tumor prostate
samples resulted SPANX positive. Signals were
exclusively  within  the  nucleus  in  normal
prostate cells, whereas both nuclear and cyto-
plasmic positivity was observed in tumor cells.
In  conclusion,  these  findings  showed  that
SPANX  genes  are  expressed  in  both  normal
and  tumor  prostate  gland,  but  the  latter
showed a peculiar cytoplasmic staining posi-
tivity.  This  suggests  a  possible  association
between SPANX over expression and prostate
cancer  development.  Additional  studies  are
needed to corroborate this hypothesis.
Introduction
Prostate cancer, one of the most commonly
diagnosed male malignancies in Western coun-
tries, is now the leading cause of cancer-relat-
ed death in men.
1 Over the years, genetic epi-
demiological  evidence  has  accumulated  in
favor of a considerable hereditary component
in prostate cancer susceptibility. Genetic link-
age analysis in 360 hereditary prostate cancer
pedigrees revealed the presence of a hereditary
prostate cancer susceptibility gene(s) at Xq27-
28  (HPCX).
2 In  agreement  with  this  finding,
further data were obtained by analyzing linkage
disequilibrium of molecular markers of X chro-
mosome in a Finnish X haplotype.
3 Xq27 is a
region containing a number of genes important
in cancer and embryonic development, includ-
ing  the  sperm  protein  associated  with  the
nucleus in the X chromosome (SPANX) gene
family
4,5 that  consists  of  the  two  subfamilies
SPANX-N and  SPANX-A/D (Human  genome
build 37.1). SPANX-A/D genes map within seg-
mental  duplications,
6,7 which  are  regions
involved in genomic rearrangements resulting
in an abnormally high level of structural poly-
morphisms.
8 Accordingly, the SPANX-B and the
SPANX-C genes were shown to be present in a
variable number of copies (ranging from one to
>11) in the normal population;
4,7 however, no
association  was  found  between  SPANX  copy
number  and  the  occurrence  of  hereditary
prostate cancer by the genetic locus described
by  Xu,
2 thus  leaving  uncertain  the  possible
identification of the aforementioned locus with
SPANX gene cluster.
9
SPANX proteins are normally expressed in
germ  cells;
4,10 however,  their  expression  has
also  been  detected  in  a  number  of  tumors,
including melanoma, myeloma, glyoblastoma,
breast carcinoma, prostate cancer, and testicu-
lar germ cell tumors.
5,11-14The present study was
undertaken  to  evaluate  the  expression  of
SPANX proteins in normal prostate tissues and
in prostate cancer by immunohistochemistry.
Materials and Methods
Patients
The analysis was carried out on 15 normal
(at autopsy) donors and 12 men with prostate
cancer  following  radical  prostatectomy.
Patients (71.7±1.8 years) and normal controls
(74.5±1.3  years)  had  a  similar  mean  age
(Table  1).  Patients’  histological  diagnosis,
Gleason scores and pre-surgery serum PSA lev-
els are shown in Table 1.
The protocol was approved by the internal
Institutional  Review  Board  and  an  informed
written  consent  was  obtained  from  each
patient with prostate cancer or, if deceased, by
his relatives.
Immunohistochemical staining
Four  mm  formalin-fixed  and  paraffin-
embedded  prostate  sections  were  processed
following  the  standard  protocol  previously
described.
5 We did not observe any time-relat-
ed effect on immunostaining with the antibody
used for this study nor with any other antibody
used for diagnosis. A polyclonal serum against
the  common  SPANX  epitope  TPTGDSDPQP,
developed in mouse, was used, as reported in a
previous  study.
4 As  negative  control,  anti-
SPANX  serum  was  pre-incubated  with  the
immunizing peptide (100 ng) for 1 h. Tissues
were visually scored at 20X magnification for
SPANX positivity; the fraction of SPANX-posi-
tive  cells  was  evaluated  independently  in  a
blinded fashion by two of us in microscopic
fields  where  non  prostatic  cells  (infiltrating
leukocytes,  fibroblasts,  etc.)  were  as  few  as
possible. Since no significant difference was
observed between the two observers, a mean
value was used.
Statistical analysis
Results  were  expressed  as  mean±SEM.
Comparisons  between  the  percentages  of
SPANX-positive cells were carried out by the
Student’s t test (SPSS 9.0 software package for
Windows). P<0.05 were considered statistical-
ly significant.
Results
Normal tissues showed only a SPANX-posi-
tive nuclear signal in 6 samples out of the 15
examined (40%), with a mean of 21.7±7.2%
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cells with SPANX-positive nuclei (Figure 1 A,
C; Table 1). The expression of SPANX was also
evaluated in 12 samples of prostate carcinoma
with  a  mean  Gleason  score  of  3.5±0.2  and
3.2±0.2 and a grading ranging from G1 to G3.
Five  samples  exhibited  a  SPANX-positive
nuclear  signal  (41.7%)  with  a  mean  of
32.9±11.8%  positive  nuclei  (Figure  1  B,  D;
Table  1).  Moreover,  cytoplasmic  staining  for
SPANX was observed in the 27.5±9.9% of the
cells (range: 60-75). None of the controls, ana-
lyzed in parallel, exhibited cytoplasmic stain-
ing (P<0.001 vs. prostate carcinoma samples).
No cytoplasmic staining was observed in the
absence of nuclear staining in prostate cancer
tissue (Table 1).
Discussion
This is the first demonstration that SPANX
genes are expressed in a normal somatic tis-
sue,  apart  the  already  known  expression  in
germ cells.
4,5 The percentage of cells showing a
SPANX-positive nuclear staining was compara-
ble both in normal and in pathologic tissues;
prostate cancer cells showed also a cytoplasmic
staining. This peculiar feature of SPANX stain-
ing, if confirmed by larger cohort studies, may
be of clinical usefulness for the immunohisto-
chemical differential diagnosis of prostate car-
cinoma. Cytoplasmic SPANX labeling is a com-
mon finding in malignant cancer cells, such as
embryonal carcinomas
5 and melanomas.
15,16 In
addition, evidences of cytoplasmic labeling in
melanomas has been shown by Westbrook et
al.
17 On the basis of extensive observations of
histological samples, we believe that the cyto-
plasmic signal represents a leakage of SPANX
proteins from the nucleus. A definitive answer
will  require  the  study  of  tumor  cells  lines
expressing SPANX. It is conceivable that simi-
lar events, which have the potential of altering
the regulation of gene expression, may also be
present in malignant cells. The similar fraction
of SPANX positive cells in normal and cancer
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Table 1. Characteristics of healthy prostate tissue donors and of patients who underwent radical prostatectomy for prostate carcinoma.
Normal prostate (autopsy) Prostate carcinoma (radical prostatectomy)
ID Age Positive Positive cell  ID Age PSA pT N Gleason G Positive Positive cell 
(years) cell  cytoplasm (%) (years) (ng/mL) score cell  cytoplasm (%)
nuclei (%) nuclei (%)
0.1 63 00 1 72 7.8 pT3 0 4+3 G2 80 70
0.2 77 00 2 63 9.2 pT3 0 4+4 G3 00
0.3 72 55 03 79 8.7 pT3 NA 4+4 G3 00
0.4 71 60 04 70 7.6 pT3 0 3+3 G2 75 65
0.5 68 00 5 72 11.6 pT3 NA 4+3 G2 80 60
0.6 80 00 6 79 6.8 pT2b NA 3+3 G2 00
0.7 79 55 07 72 8.2 pT3 0 3+2 G1 75 60
0.8 77 00 8 77 9.6 pT2b 0 3+4 G2 00
0.9 76 50 09 74 10.1 pT3 NA 4+4 G2 00
0.10 80 00 10 73 9.9 pT3 0 4+3 G2 00
0.11 71 60 0 11 57 8.7 pT3 0 4+3 G2 85 75
0.12 74 00 12 72 9.5 pT2b 0 2+2 G1 00
0.13 79 00
0.14 72 00
0.15 78 45 0
ID, identification; PSA, prostate specific antigen; pT, tumor stage; N, lymphonodes; NA, lymphonodes not excissed; G, grading.
Figure 1. Immunohistochemistry of prostate. (A) Normal prostatic tissue; (B) prostate
carcinoma (A, B Hematoxylin counterstain; bar = 800 mm); (C) normal prostatic tissue
(Hematoxylin counterstain; bar = 200 mm); (D) prostate carcinoma (Hematoxylin coun-
terstain; bar = 80 mm).[page 182] [European Journal of Histochemistry 2010; 54:e41]
tissues suggests that the expression of SPANX
genes in prostate carcinomas correlates with
their expression in normal cells from which
the tumor originates: a finding similar to what
previously  described  in  seminomas,
5 where
nonetheless  the  nuclear  positivity  involves
approximately  100%  of  the  cells.  Since  our
antibody was generated by immunizing mice
with a synthetic peptide, which sequence is
shared by almost all known SPANX proteins,
4
we cannot differentiate SPANX-B form SPANX-
A-like subfamilies. Although this is a limiting
aspect, we believe that, given the high homol-
ogy  among  SPANX  gene  family  members,  it
would be difficult to assess the specificity of
any antibody for a SPANX subfamily or for a
single  member,  especially  for  immunohisto-
chemical purposes. In conclusion, the present
findings  showed  that  SPANX  expression  is
physiological in 40% of normal individuals, at
least in the Sicilian sample examined in this
study. This might relate to predisposing haplo-
types of SPANX locus.
3The similar incidence of
SPANX-positive cells in normal and neoplastic
tissues, although suggestive, is not sufficient
to establish a causative relationship between
SPANX expression and prostate cancer tissues,
and  deserves  more  detailed  studies  in  addi-
tional patients. 
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